Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, B-Cell 2Cytokine Release Syndrome 2Burkitt Lymphoma 2Pancreatic Neoplasms 1Neurotoxicity Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Early Stage Triple Negative ER Low Breast Cancer 1Disease Progression 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 53Vincristine 33blinatumomab 30Prednisone 28Methotrexate 28Cytarabine 26Dexamethasone 24Specimen Handling 21Rituximab 21Doxorubicin 20merphos 19Mercaptopurine 19Etoposide 18prednylidene 17fludarabine 17deltacortene 17Calcium Dobesilate 17Biopsy 17dexamethasone acetate 16dexamethasone 21-phosphate 16auricularum 16N,N-dicyclohexyl-isoborneol-10-sulfonamide 16azathiopurine 15Inotuzumab Ozogamicin 15pegaspargase 14venetoclax 13Leucovorin 13CT-P10 13Asparaginase 13Spinal Puncture 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Burkitt Lymphoma × Interleukin 1 Receptor Antagonist Protein × 1 year × Clear all
NCT04148430 2025-11-05

A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
62 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell

NCT06703216 2025-06-15

PACER

Ann & Robert H Lurie Children's Hospital of Chicago

Phase 1/2 Not yet recruiting
24 enrolled
Lymphoid

Cytokine Release Syndrome, Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡